Trade

with

Data not available

Open

-

Previous Close

-

Volume (Avg)

-

Day's Range

-

52Wk Range

-

Market Cap.

-

P/E Ratio (EPS

-

Dividend Rate ( Yield )

-

Beta

2.90

Shares Outstanding

34.12M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-16.23M
Operating Margin
-
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-2.48
Ownership

Institutional Ownership

-

Top 10 Institutions

171.84%

Mutual Fund Ownership

1.17%

Float

-

5% / Insider Ownership

-

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • FCP OP MEDICAL BioHealthTrends

  •  

    165,794

  • 0.00

  • 0.48

  • I.B.I Global Equity

  •  

    84,000

  • 5.00

  • 0.25

  • APO Medical Opportunities

  •  

    61,850

  • 0.00

  • 0.18

  • Harel Selected BioMed

  •  

    49,000

  • -9.26

  • 0.15

  • PHARMA/wHEALTH

  •  

    26,056

  • 0.00

  • 0.08

  • RIM Global CC Bioscience

  •  

    13,600

  • 0.00

  • 0.04

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fcmi Financial Corp Et AL

  •  

    34,803,965

  • +350.01%

  • 144.12

  • Sabby Management LLC

  •  

    2,021,347

  • +6.23%

  • 5.92

  • SENVEST INTERNATIONAL LLC

  •  

    1,591,367

  • +2.68%

  • 4.66

  • Bvf Inc

  •  

    1,501,000

  • +87.62%

  • 4.40

  • OrbiMed Israel GP Ltd

  •  

    1,135,000

  • -57.44%

  • 4.70

  • Orbimed Advisors, LLC

  •  

    1,135,000

  • 0.00%

  • 3.33

  • Opaleye Management Inc

  •  

    650,000

  • -55.20%

  • 1.91

  • Sphera Funds Management Ltd.

  •  

    600,000

  • 0.00%

  • 1.76

  • Oppenheim Asset Mgmt Services S.à r.l.

  •  

    191,850

  • +58.88%

  • 0.56

  • Medical Strategy GmbH

  •  

    165,794

  • 0.00%

  • 0.48

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

-

Style

Small Value

Bioline Rx Ltd was incorporated in April 2003. It is a clinical stage biopharmaceutical development company, engaged in identifying, in-licensing and developing therapeutic candidates that have advantages over currently available the...morerapies or that address unmet medical needs. The Company's development pipeline consists of six clinical-stage therapeutic candidates: BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction, or AMI; BL-8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a customized, proprietary, pen-like applicator containing a novel formulation of two acids, which is...more being developed in Europe as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an orally available treatment for the hepatitis C virus, or HCV, and other viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells. The Company has three therapeutic candidates in the preclinical stages of development. The first therapeutic candidate, BL-1040, is a novel, resorbable polymer solution for use in the reduction or prevention of ventricular remodeling in patients who suffered an AMI. The second clinical-stage therapeutic candidate, BL-8040, is a novel, short peptide that functions as a high-affinity antagonist for CXCR4 used to develop for AML, stem cell mobilization and other hematological indications. The third clinical-stage therapeutic candidate, BL-7010, is a novel, non-absorbable, orally available, high-molecular-weight co-polymer used for the treatment of celiac disease.lessless

Key People

Dr. Kinneret Savitsky, PhD

CEO

Dr. Aharon Schwartz,PhD

Chairman of the Board/Director

Mr. Philip Serlin

CFO/COO

Mr. David Malek

Vice President, Divisional

Dr. Arnon Aharon, M.D.

Vice President, Divisional

  • Bioline Rx Ltd

  • 19 Hartum Street

  • Jerusalem, 9777518

  • ISR.Map

  • Phone: +972 25489100

  • Fax: +972 25489101

  • biolinerx.com

Incorporated

2003

Employees

43

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: